Dissemination feature based on PET/CT is a risk factor for diffuse large B cell lymphoma patients outcome

Area of Science:

• Oncology
• Radiology
• Medical Imaging

Background:

• ¹⁸F-FDG PET/CT is crucial for assessing lymphoma lesion dissemination.
• Dmax, the distance between the farthest PET/CT lesions, shows promise in predicting Diffuse Large B-cell Lymphoma (DLBCL) outcomes.
• This study validates Dmax's impact on a large DLBCL cohort.

Purpose of the Study:

• To analyze the impact of Dmax on the outcomes of DLBCL patients.
• To compare Dmax with Metabolic Bulk Volume (MBV) and Eastern Cooperative Oncology Group performance status (ECOG PS).
• To develop a new prognostic index (DRPI) for DLBCL risk stratification.

Main Methods:

• Retrospective analysis of 253 newly diagnosed DLBCL patients.
• Recorded baseline Dmax, clinical data, and survival information.
• Measured MBV and performed multivariate analysis to identify independent prognostic factors.

Main Results:

• Dmax significantly impacted progression-free survival (PFS) and overall survival (OS) (p < 0.001).
• A Dmax revised prognostic index (DRPI) combining Dmax and ECOG PS outperformed the International Prognostic Index (IPI).
• The DRPI identified an ultra-risk DLBCL population with significantly poorer outcomes.

Conclusions:

• Dmax is a novel and valuable indicator for assessing lymphoma lesion dissemination and predicting DLBCL outcomes.
• Dmax significantly aids in stratifying DLBCL patients with different prognoses.
• The DRPI offers improved risk stratification for DLBCL patients.